丙戊酸钠与左乙拉西坦治疗儿童原发性癫痫的效果比较

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (523 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect and adverse reactions of Sodium Valproate Sustained Release Tablets and Levetiracetam Tablets in children with primary epilepsy. Methods A total of 100 children with primary epilepsy admitted to the Second People’s Hospital of Lianyungang, Jiangsu Province from January 2020 to February 2021 were selected as the study objects. According to random number table method, they were divided into experimental group and control group, with 50 cases in each group. The control group received Sodium Valproate Sustained Release Tablets, and the experimental group received Levetiracetam Tablets. Blood drug concentration, clinical effect, electroencephalogram evaluation results, and the occurrence of adverse reactions were observed and compared between two groups after six months of treatment. Results The average blood drug concentration of control group was (69.73±30.15) μg/ml; and the average blood drug concentration of experimental group was (13.92±4.76) mg/ml. The total effective rate of experimental group was higher than that of control group, and the difference was statistically significant (P < 0.05). The correction rate of electroencephalogram in experimental group was higher than that in control group, and the difference was statistically significant (P < 0.05). There was no statistical difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion Levetiracetam Tablets monotherapy is superior to Sodium Valproate Sustained Release Tablets in the treatment of children with primary epilepsy, and has certain safety.

Key words： Epilepsy Children Sodium Valproate Sustained Release Tablets Levetiracetam Tablets Therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Lin MA Suqing▲ BI Jinzhu

Cite this article:

LU Lin MA Suqing▲ BI Jinzhu. Effect comparison of Sodium Valproate Sustained Release Tablets and Levetiracetam Tablets in the treatment of children with primary epilepsy[J]. 中国医药导报, 2022, 19(14): 84-87.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I14/84

[1] Camfield P，Camfield C. Incidence，prevalence and aetiology of seizures and epilepsy in children [J]. Epileptic Disord，2015，17（2）：117-123.
[2] 王晓江，李秋.迷走神经刺激术治疗儿童药物难治性癫痫研究进展[J].贵州医药，2020，44（2）：205-207.
[3] Li J，Yang D，Zhao D，et al. Efficacy of phenobarbital and sodium valproate in treating convulsive epilepsy in rural northeast China [J]. Seizure，2019，71：207-213.
[4] Nolan D，Lester SG，Rau SM，et al. Clinical Use and Efficacy of Levetiracetam for Absence Epilepsies [J]. J Child Neurol，2019，34（2）：94-98.
[5] Fisher RS，Acevedo C，Arzimanoglou A，et al. ILAE official report：a practical clinical definition of epilepsy [J]. Epilepsia，2014，55（4）：475-482.
[6] Fisher RS，Cross JH，French JA，et al. Operational classification of seizure types by the International League Against Epilepsy：Position Paper of the ILAE Commission for Classification and Terminology [J]. Epilepsia，2017，58（4）：522-530.
[7] Herta J，Dorfer C. Surgical treatment for refractory epilepsy [J]. J Neurosurg Sci，2019，63（1）：50-60.
[8] van der Poest CE，Jansen FE，Braun K，et al. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex [J]. Paediatr Drugs，2020，22（1）：73-84.
[9] Lyttle MD，Rainford N，Gamble C，et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus （EcLiPSE）：a multicentre，open-label，randomised trial [J]. Lancet，2019，393（1）：2125-2134.
[10] 中华医学会儿科学分会神经学组.新诊断儿童癫痫的初始单药治疗专家共识[J].中华儿科杂志，2015，53（10）：734-737.
[11] Garcia-Cortes M，Lucena MI，Pachkoria K，et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury [J]. Aliment Pharmacol Ther，2008，27（9）：780-789.
[12] Ferro MA，Avery L，Fayed N，et al. Child- and parent-reported quality of life trajectories in children with epilepsy：A prospective cohort study [J]. Epilepsia，2017， 58（7）：1277-1286.
[13] Sekimoto H，Rikitake Y. Efficacy and safety of levetiracetam in Japanese epilepsy patients：A retrospective cohort study [J]. J Clin Pharm Ther，2019，44（6）：912-923.
[14] 王慧玲，张涛志，尹续续，等.WHO儿童基本药物目录与国家基本药物目录中的抗癫痫药对比分析[J].中国药房，2020，31（20）：2452-2457.
[15] Halma E，de Louw AJ，Klinkenberg S，et al. Behavioral side-effects of levetiracetam in children with epilepsy：a systematic review [J]. Seizure，2014，23（9）：685-691.
[16] Vasquez A，Gainza-Lein M，Abend NS，et al. First-line medication dosing in pediatric refractory status epilepticus [J]. Neurology，2020，95（19）：e2683-e2696.
[17] Mazur RD，Wang Ba Q，Kato Bs K，et al. Effectiveness of Levetiracetam Monotherapy in Pediatric Patients With Epilepsy [J]. J Child Neurol，2019，34（10）：593-597.
[18] Garg N，Joshi R，Medhi B. A novel approach of targeting refractory epilepsy：Need of an hour [J]. Brain Res Bull，2020，163（1）：14-20.
[19] Caraballo R，Silva S，Beltran L，et al. Childhood-only epilepsy with generalized tonic-clonic seizures：A well-defined epileptic syndrome [J]. Epilepsy Res，2019，153（1）：28-33.
[20] 陆菲，张若男，邵俞.维生素B6联合左乙拉西坦治疗小儿难治性癫痫的疗效及对血清NSE水平的影响[J].中国妇幼保健，2021，36（3）：616-618.
[21] 贾永飞，董建鹏.左乙拉西坦单药在小儿癫痫治疗中的安全性及可行性[J].山西医药杂志，2018，47（19）：2313-2315.
[22] 乔喜娟，贺孝良.左乙拉西坦和丙戊酸钠对癫痫患儿骨代谢的影响[J].新乡医学院学报，2020，37（9）：881-884.
[23] 杜雅坤，陈芳，王磊，等.左乙拉西坦对部分性癫痫患儿脑电图和认知功能的影响研究[J].中国全科医学，2019， 22（14）：1689-1695，1701.
[24] 张丽霞，王一晶.左乙拉西坦对癫痫患儿主穹窿蛋白水平及认知功能的影响[J].中国神经免疫学和神经病学杂志，2019，26（1）：40-43.
[25] 幸鸿宇，刘丕松，杨一海，等.左乙拉西坦治疗小儿癫痫的效果及对认知功能的影响[J].中国医药导报，2019， 16（27）：122-125.
[26] 周定富，王萍，何颖慧.左乙拉西坦对癫痫患儿骨代谢与认知功能的影响[J].中外医学研究，2020，18（4）：26-27.